Application for Authority to Prescribe or Supply a Schedule 8 Cannabis Medicine for Human Therapeutic Use





Schedule 8 cannabis medicines include medicines derived from the cannabis plant, including nabiximols, and synthetic substances such as dronabinol and nabilone.

An application to NSW Ministry of Health for prescribing or supplying a Schedule 8 cannabis medicine is required where the patient is:

- a drug dependent person (including a person treated under the Opioid Treatment Program); or
- a child aged under 16 years

Applications to prescribe and supply extemporaneously-compounded cannabis medicine are to be made using <u>Application for Authority to Prescribe or Supply an Unregistered or (Pharmacy) Extemporaneously-Compounded Schedule 8</u>
Product for Human Therapeutic Use.

All applications to prescribe and supply a Schedule 8 Cannabis Medicine for a clinical trial are to be made using <u>Application for Authority to Prescribe</u> and Supply a Substance for the Purpose of Human Research.

Are you prescribing or supplying:

A registered schedule 8 cannabis medicine. Go to 'Before starting the application'

An unregistered schedule 8 cannabis medicine. Before prescribing or supplying an unregistered medicine, approval under the *Therapeutic Goods Act 1989* (Commonwealth) must be granted. Indicate under which scheme you are operating:

Authorised Prescriber Scheme:

I am approved as an authorised practitioner to treat specified patients, with certain clinical indications. Authorised Prescriber approval number

(please s	specify)
-----------	----------

For more information, visit <u>Therapeutic</u> <u>Goods Administration (TGA) Authorised</u> <u>Prescriber Scheme</u> Go to 'Before starting the application'

Special Access Scheme (SAS): Use the TGA's SAS Online System. You do not need to complete this application when using the TGA system.

Before starting the application, please make sure that you have:

- Contacted the authorised Opioid Treatment Program prescriber if the patient is currently enrolled on the Opioid Treatment Program (OTP) and have obtained written agreement from the OTP prescriber supporting the treatment.
- Explained the following to the patient:
 - unregistered medicines have not been assessed for safety or efficacy by the TGA
 - the nature of the treatment and potential harms (and obtained patient consent)
 - for products containing tetrahydrocannabinol, that driving, and workplace health and safety need to be considered when planning activities
 - why their personal health information is collected, how they can access their information, how it may be used, and who it may be disclosed to (see Privacy Statement below).

health.nsw.gov.au 1/5

Application for Authority to Prescribe or Supply a Schedule 8 Cannabis Medicine for Human Therapeutic Use





Clinical Advice and Support

The NSW Ministry of Health recommends the use of SafeScript NSW to assist practitioners to make informed clinical decisions https://www.safescript.health.nsw.gov.au/. Consider checking SafeScript NSW for evidence of alerts or other issues related to the prescribing and supply of high-risk monitored medicines.

The NSW Ministry of Health recommends that all prescribing and supply is in accordance with the approved Product Information (PI) and with published recommendations.

The TGA has a responsibility to encourage the use of medicines that are included in the Australian Register of Therapeutic Goods (ARTG), as these products have been evaluated to ensure they meet strict standards of safety, quality, and effectiveness. For this reason, it is expected that practitioners (prescribers) will have considered all clinically appropriate treatment options that are included in the ARTG before applying to access an unapproved cannabis medicine.

Applicants can contact experienced clinical advisors and can access relevant medical specialists to obtain general clinical advice and support when managing patients, by calling the free *SafeScript NSW Clinical Advice Line (SCAL)* on *1800 434 155*, available 24/7. This advice line cannot provide support for an application for an authority.

Applicants are advised to consider if the patient would benefit from a review by an addiction medicine specialist to manage any perceived drug dependence concerns.

Applicants can contact experienced clinical advisors and addiction medicine specialists to obtain general clinical advice and support when managing patients with drug and alcohol issues, by calling the free Drug & Alcohol Specialist Advisory Service (DASAS) on Metropolitan Area: (02) 8382-1006; Regional, Rural & Remote NSW: 1800 023 687, available 24/7. This advice line cannot provide support for an application for an authority.

All NSW community general practitioners and rural clinicians can contact HNELHD-JHHPharmacy@ health.nsw.gov.au for expert clinical guidance and

advice on prescribing cannabis medicines. Health practitioners working in public facilities in metropolitan local health districts should consult their local medicines information service. Further information can be found at Cannabis medicines

Privacy Statement: The information set out in this form is required by the NSW Ministry of Health for the issuance of an authority to prescribe or supply a Schedule 8 medicine as required under the law. The collection, use and disclosure of the information provided will be in accordance with privacy laws. Information collected as part of the application process may be used and disclosed as part of assessing the application. Medicare numbers may be used for the purpose of patient identification. Practitioner information, and data regarding the number of patients for whom they hold authorities to prescribe or supply a Schedule 8 medicine, may also be used, and disclosed for policy and planning purposes. The information collected may be disclosed to health practitioners when necessary to facilitate coordination of treatment and patient safety or where required or authorised by law. The application may not be processed if all information and all declarations requested on the form are not completed. For further information on privacy, visit http://www.health.nsw.gov.au/patients/privacy

I confirm that I have read and understood all the information above including 'Clinical Advice and Support' and the 'Privacy Statement'

(This declaration is mandatory and must be completed)

Submitting the application:

Fax completed form to the Pharmaceutical Regulatory Unit: Fax: **(02) 9424 5860** or email to: MOH-CannabisMedicinesApplicationsNSW@health.nsw.gov.au

Enquiries:

Please direct any enquiries to the Pharmaceutical Regulatory Unit: Tel: **(02) 9391 9944** email: MOH-CannabisMedicinesApplicationsNSW@health.nsw.gov.au

Processing Time:

Please allow up to **2 business days** for the processing of applications. Additional application processing time for patients under 16 years of age is required to obtain exemption under the *Children and Young Persons (Care and Protection) Act* 1998 (CYPCPA). CYPCPA Exemption may take up to **21 days**. Contact Pharmaceutical Regulatory Unit for any additional information.

health.nsw.gov.au 2/5

Application for Authority to Prescribe or Supply a Schedule 8 Cannabis Medicine for Human Therapeutic Use



as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

SECTION A - PRESCRIB	ER DETAILS		
Prescriber Name: (as displayed in	AHPRA)		
First Name:		Middle Name(s): _	
Family Name:			
Name of Practice:			
Address:		Suburb/town:	
Postcode:	Telephone:		Fax:
Mobile:			
Email:			(please note this email address will be used for all correspondence)
AHPRA Registration No.:		PBS Prescriber No	.:
SECTION B - PATIENT D	DETAILS		
Patient Name: (as shown on Medic	care card)		
First Name:		Middle Name(s):	
Family Name:			
Patient also known as: (if applica	able)		
First Name:		Middle Name(s): _	
Family Name:			
Address:		Suburb/town:	
Postcode:	Medicare number: (if app	licable)	Ref no.:
DVA number: (if applicable)			
DOB:	(dd/mm/yyyy) Sex:	Male Female	Another term

health.nsw.gov.au 3/5

Application for Authority to Prescribe or Supply a Schedule 8 Cannabis Medicine for Human Therapeutic Use



as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

SECTION C - IS AN AUTHORITY REQUIRED?

1. DO YOU CONSIDER THIS PATIENT TO BE DRUG DEPENDENT?

A 'drug dependent person' means a person who has acquired, as a result of repeated administration of:

- (a) a drug of addiction, or
- (b) a prohibited drug within the meaning of the Drug Misuse and Trafficking Act 1985,

an overpowering desire for the continued administration of such a drug. (section 27 of the Poisons and Therapeutic Goods Act 1966).

No. Authority is NOT required for this patient at this time.

Is the patient under 16 years

Yes. The NSW Ministry of Health will seek an exemption under the Children and Young Persons (Care and Protection) Act 1998 on your behalf. Go to Section D: Cannabis Medicine Authorisation Details, further details are required to seek this exemption

No. Prescribing may continue without authority from the NSW Ministry of Health.

Yes. Authority required.

Is the patient under 16 years

Yes. In addition to requiring an authority, an exemption under the *Children and Young Persons* (*Care and Protection*) *Act 1998* is needed. The NSW Ministry of Health will seek this exemption on your behalf. **Go to question 2**

No. Go to question 2

2. IS THE PATIENT CURRENTLY ENROLLED ON THE OPIOID TREATMENT PROGRAM (OTP)

No. Go to Section D: Cannabis Medicine Authorisation Details

Yes. I am the authorised OTP prescriber. Go to Section D: Cannabis Medicine Authorisation Details

Yes. I am <u>NOT</u> the authorised OTP prescriber. Has the patient been reviewed by the authorised OTP prescriber and written agreement to the proposed treatment obtained?

Yes. Go to Section D: Cannabis Medicine Authorisation Details

No. Contact the authorised OTP prescriber and obtain written agreement before submitting this application. This application **cannot proceed** and will not be considered until written agreement is obtained.

health.nsw.gov.au 4/5

Application for Authority to Prescribe or Supply a Schedule 8 Cannabis Medicine for Human Therapeutic Use



as required under the Poisons and Therapeutic Goods Act 1966 (NSW)

SECTION D - CANNABIS MEDICINE AUTHORISATION DETAILS				
Indication: (state for patients aged under 16 years only):				
Unregistered cannabis medicines (specify):				
Active ingredient:				
Trade name:				
ARTG registered cannabis medicine Nabiximols				
Route of administration:	Maximum daily dose:	mg		
Other (specify):				
Route of administration:	Maximum daily dose:	mg		
SECTION E - DECLARATION				
I confirm that the information I have provided in th knowledge and where required, that I have sought appropriate medical specialist for the proposed tr	a review and obtained written agreement fr			
Signature: Print and Sign	Date: (dd/mm/y	уууу)		

health.nsw.gov.au SHPN (LRS) 230556 © NSW Health August 2023 5/5